| Symbol | CRMD |
|---|---|
| Name | CORMEDIX INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 300 CONNELL DRIVE,SUITE 4200, BERKELEY HEIGHTS, New Jersey, 07922, United States |
| Telephone | +1 908 517-9500 |
| Fax | — |
| — | |
| Website | https://www.cormedix.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001410098 |
| Description | Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs. Additional info from NASDAQ: |
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
Read more(90% Positive) CORMEDIX INC. (CRMD) Announces Clinical Development Update
Read moreCorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Read moreNew Form SCHEDULE 13G/A - CorMedix Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001102 <b>Size:</b> 7 KB
Read more